Autres langues Elicera Therapeutics AB

Actions

ELIC

SE0015382080

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:29:49 17/05/2024			Varia. 5j.	Varia. 1 janv.
1,065 ^SEK	+8,67%		+13,30%	-76,64%

28/03	Elicera Therapeutics AB (publ) annonce des changements d'administrateurs	CI
06/03	Elicera conclut un accord avec un important centre de cancérologie américain pour évaluer l'utilisation d'ITANK dans les thérapies des récepteurs des cellules T	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Elicera Therapeutics publishes the annual report for 2023	16/04
Nomination committee proposes CMC specialist to Elicera's board of directors	28/03
Elicera Therapeutics AB Announces Director Changes	28/03
Elicera Therapeutics changes Certified Adviser and Liquidity provider to Mangold Fondkommission AB	22/03
Elicera Therapeutics announces outcome in rights issue	11/03
BioStock: Elicera collaborates with US cancer centre to evaluate iTANK	07/03
Elicera enters agreement with prominent US Cancer Center to evaluate the use of iTANK in T-cell receptor therapies	06/03
Elicera Enters Agreement with Prominent US Cancer Center to Evaluate the Use of ITANK in T-Cell Receptor Therapies	06/03
Elicera Therapeutics receives additional subscription commitments from the board and management in the ongoing rights issue	04/03
The subscription period in Elicera Therapeutics' rights issue of units starts today	23/02
Elicera Therapeutics publishes prospectus in connection with rights issue of units	21/02
BioStock: Full speed ahead for Elicera in 2024	19/02
Elicera Therapeutics' abstract on the iTANK platform's potential to enhance CAR T-cell treatment of solid tumors accepted for presentation at ISCT 2024	16/02
Elicera Therapeutics AB to Present at the Scientific Conference International Society for Cell & Gene Therapy Meeting 2024 in Vancouver, Canada, May 28 to June 1	16/02
Elicera invites to investor meetings on February 28[th] and 29[th] 2024	16/02
BioStock: Elicera gets green light for CAR T clinical study	14/02
Elicera Therapeutics AB Receives Conditional Approval from the Medical Products Agency on Its Car T-Cell Clinical Trial Application to Test ELC-301	14/02
Elicera Therapeutics AB (publ) Year-End Report 1 January - 31 December 2023	13/02
Elicera Therapeutics AB Reports Earnings Results for the Full Year Ended December 31, 2023	13/02
Elicera Therapeutics AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Elicera Therapeutics AB

Actions

ELIC

SE0015382080

Autres langues

Filtres